Progressive multifocal leukoencephalopathy following treatment with bendamustine and rituximab

A 66-year-old female developed progressive multifocal leukoencephalopathy (PML) 17 months after treatment with bendamustine and rituximab chemoimmunotherapy. During her evaluation for PML, she was found to have a CD4 count of 176 cells/μL (reference range 492–1740). The patient demonstrated spontane...

Full description

Saved in:
Bibliographic Details
Published in:International journal of hematology 2012-08, Vol.96 (2), p.274-278
Main Authors: Warsch, Sean, Hosein, Peter J., Morris, Michele I., Teomete, Uygar, Benveniste, Ronald, Chapman, Jennifer R., Lossos, Izidore S.
Format: Article
Language:English
Subjects:
Aged
Antibodies, Monoclonal, Murine-Derived - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bendamustine Hydrochloride
Biological and medical sciences
Biopsy
Brain - pathology
Case Report
Female
Hematologic and hematopoietic diseases
Hematology
Human viral diseases
Humans
Infectious diseases
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Leukoencephalopathy, Progressive Multifocal - chemically induced
Leukoencephalopathy, Progressive Multifocal - diagnosis
Lymphoma, Mantle-Cell - complications
Lymphoma, Mantle-Cell - drug therapy
Magnetic Resonance Imaging
Medical sciences
Medicine
Medicine & Public Health
Nitrogen Mustard Compounds - administration & dosage
Oncology
Rituximab
Viral diseases
Viral diseases of the nervous system
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 66-year-old female developed progressive multifocal leukoencephalopathy (PML) 17 months after treatment with bendamustine and rituximab chemoimmunotherapy. During her evaluation for PML, she was found to have a CD4 count of 176 cells/μL (reference range 492–1740). The patient demonstrated spontaneous recovery of symptoms that occurred in parallel with recovery of the CD4 counts. While PML is associated with rituximab therapy, the timing and patients’ clinical course are atypical, raising the possibility of a previously unreported association with bendamustine therapy.
ISSN:0925-5710
1865-3774
DOI:10.1007/s12185-012-1118-6